All Stories

  1. Extended D-dimer cut-offs and machine learning for ruling out pulmonary embolism in individuals undergoing computed tomography pulmonary angiography
  2. Methionine supplementation: potential for improving alveolar macrophage function through reverse cholesterol transport?
  3. The Utility of Gallium-68 DOTATOC PET/CT in Lymphangioleiomyomatosis
  4. Remote monitoring of oxygen saturation in individuals with COVID-19 pneumonia
  5. Neutrophil extracellular traps activate IL-8 and IL-1 expression in human bronchial epithelia
  6. Prevalence of comorbid asthma in COVID-19 patients
  7. Recent Insights into In Utero Gene Editing, Checkpoint Inhibitors, and Polymorphonuclear Extracellular Vesicles
  8. Lymphangioleiomyomatosis: a clinical review
  9. The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-...
  10. Vaping-associated lung injury
  11. A 34-Year-Old Man With a Chylothorax and Bony Pain
  12. Pulmonary Alveolar Proteinosis Syndrome
  13. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency
  14. Increased Pulmonary GM-CSF Causes Alveolar Macrophage Accumulation. Mechanistic Implications for Desquamative Interstitial Pneumonitis
  15. Emerging Approaches to Predict Prognosis and Monitor Disease Progression in Lymphangioleiomyomatosis
  16. The Alveolar Lipidome in Pulmonary Alveolar Proteinosis. A New Target for Therapeutic Development?
  17. Exosomes form EGFR-mutated adenocarcinoma induce tumour invasion
  18. Long-Term Safety and Efficacy of Gene-Pulmonary Macrophage Transplantation Therapy of PAP in Csf2ra−/− Mice
  19. Shaping the future of an ultra-rare disease
  20. Recurrent Sinusitis, Lower Limb Edema, and Nail Changes
  21. Automated Parenchymal Pattern Analysis of Treatment Responses in Pulmonary Alveolar Proteinosis
  22. An Approach to Precision Medicine for Pulmonary Alveolar Proteinosis
  23. Cystic Fibrosis Disease Severity Correlates with Biomarkers of Elastin Degradation
  24. US National Pulmonary Alveolar Proteinosis Registry: Update on Differential Diagnosis, Clinical Manifestations, and Current Therapy
  25. Cystic fibrosis disease severity correlates with plasma levels of desmosine and isodesmosine, biomarkers of elastin degradation
  26. Pulmonary alveolar proteinosis
  27. Sweat Chloride Testing
  28. Blood Testing for Differential Diagnosis of Pulmonary Alveolar Proteinosis Syndrome
  29. Blood testing in the diagnosis of pulmonary alveolar proteinosis
  30. Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
  31. Prevalence and healthcare burden of pulmonary alveolar proteinosis
  32. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis
  33. Glycosylation Repurposes Alpha-1 Antitrypsin for Resolution of Community-acquired-pneumonia
  34. Reply
  35. Irish Thoracic Society Annual Scientific Meeting 2017 10th - 11th November 2017, Limerick Strand Hotel, Limerick
  36. Targeting cholesterol homeostasis in lung diseases
  37. Risk factors for totally implantable venous access device-associated complications in cystic fibrosis
  38. Genetic Variation of the α1 -Antitrypsin Gene Is Associated With Increased Autoantibody Production in Rheumatoid Arthritis
  39. Rapid urinary antigen testing for the investigation of bacteraemic respiratory pneumococcal disease; underutilised and undervalued?
  40. Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge
  41. ITS Annual Scientific Meeting 2016
  42. 021THE PREVALENCE OF POLYPHARMACY AND THE APPROPRIATENESS OF PRESCRIBING IN ADMISSIONS FROM A MEDICAL ASSESSMENT UNIT
  43. Irish Endocrine Society 40th Annual Meeting 14th and 15th October 2016, Stormont Hotel Belfast
  44. The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency
  45. Proceedings of the RAMI Intern Section Meeting, 30 January 2016, Royal College of Physicians of Ireland
  46. Unusual Acute Sequelae of α 1 -Antitrypsin Deficiency
  47. The BLT1 Inhibitory Function of α-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling
  48. AB0115 Phenotypic Variations of Alpha-One Anti-Trypsin Are Associated with Higher Titres of Ana
  49. The effect of the decoy molecule PA401 on CXCL8 levels in bronchoalveolar lavage fluid of patients with cystic fibrosis
  50. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema
  51. Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function
  52. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy
  53. The Role and Importance of Glycosylation of Acute Phase Proteins with Focus on Alpha-1 Antitrypsin in Acute and Chronic Inflammatory Conditions
  54. Airway inflammation in cystic fibrosis
  55. Galectin-9 Signaling through TIM-3 Is Involved in Neutrophil-Mediated Gram-Negative Bacterial Killing: An Effect Abrogated within the Cystic Fibrosis Lung
  56. Increased Outer Arm and Core Fucose Residues on theN-Glycans of Mutated Alpha-1 Antitrypsin Protein from Alpha-1 Antitrypsin Deficient Individuals
  57. Use of a care bundle in the emergency department for acute exacerbations of chronic obstructive pulmonary disease: a feasibility study
  58. The CF-ABLE Score
  59. A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis
  60. Pleuroperitoneal Leak Complicating Peritoneal Dialysis: A Case Series
  61. Augmentation Therapy for Alpha-1 Antitrypsin Deficiency—Not Enough Evidence to Support its Use Yet!